These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 22253088)
1. Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells. Su JS; Woods SM; Ronen SM NMR Biomed; 2012 Feb; 25(2):379-88. PubMed ID: 22253088 [TBL] [Abstract][Full Text] [Related]
2. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Venkatesh HS; Chaumeil MM; Ward CS; Haas-Kogan DA; James CD; Ronen SM Neuro Oncol; 2012 Mar; 14(3):315-25. PubMed ID: 22156546 [TBL] [Abstract][Full Text] [Related]
3. Nuclear magnetic resonance detects phosphoinositide 3-kinase/Akt-independent traits common to pluripotent murine embryonic stem cells and their malignant counterparts. Romanska HM; Tiziani S; Howe RC; Günther UL; Gulzar Z; Lalani el-N Neoplasia; 2009 Dec; 11(12):1301-8. PubMed ID: 20019838 [TBL] [Abstract][Full Text] [Related]
4. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Samartzis EP; Gutsche K; Dedes KJ; Fink D; Stucki M; Imesch P Oncotarget; 2014 Jul; 5(14):5295-303. PubMed ID: 24979463 [TBL] [Abstract][Full Text] [Related]
5. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Kondapaka SB; Singh SS; Dasmahapatra GP; Sausville EA; Roy KK Mol Cancer Ther; 2003 Nov; 2(11):1093-103. PubMed ID: 14617782 [TBL] [Abstract][Full Text] [Related]
6. The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. Al-Saffar NM; Jackson LE; Raynaud FI; Clarke PA; Ramírez de Molina A; Lacal JC; Workman P; Leach MO Cancer Res; 2010 Jul; 70(13):5507-17. PubMed ID: 20551061 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells. Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590 [TBL] [Abstract][Full Text] [Related]
8. Perifosine: update on a novel Akt inhibitor. Gills JJ; Dennis PA Curr Oncol Rep; 2009 Mar; 11(2):102-10. PubMed ID: 19216841 [TBL] [Abstract][Full Text] [Related]
9. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Papa V; Tazzari PL; Chiarini F; Cappellini A; Ricci F; Billi AM; Evangelisti C; Ottaviani E; Martinelli G; Testoni N; McCubrey JA; Martelli AM Leukemia; 2008 Jan; 22(1):147-60. PubMed ID: 17928881 [TBL] [Abstract][Full Text] [Related]
10. Perifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-κB signaling pathway in a human breast cancer cell line. Lin X; Zhang X; Wang Q; Li J; Zhang P; Zhao M; Li X Neoplasma; 2012; 59(3):248-56. PubMed ID: 22329846 [TBL] [Abstract][Full Text] [Related]
11. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells. Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171 [TBL] [Abstract][Full Text] [Related]
12. Andrejeva G; Gowan S; Lin G; Wong Te Fong AL; Shamsaei E; Parkes HG; Mui J; Raynaud FI; Asad Y; Vizcay-Barrena G; Nikitorowicz-Buniak J; Valenti M; Howell L; Fleck RA; Martin LA; Kirkin V; Leach MO; Chung YL Autophagy; 2020 Jun; 16(6):1044-1060. PubMed ID: 31517566 [TBL] [Abstract][Full Text] [Related]
13. Probing the PI3K/Akt/mTor pathway using Phyu SM; Tseng CC; Fleming IN; Smith TA Sci Rep; 2016 Nov; 6():36544. PubMed ID: 27811956 [TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells. Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893 [TBL] [Abstract][Full Text] [Related]
16. Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer. Moestue SA; Dam CG; Gorad SS; Kristian A; Bofin A; Mælandsmo GM; Engebråten O; Gribbestad IS; Bjørkøy G Breast Cancer Res; 2013 Feb; 15(1):R16. PubMed ID: 23448424 [TBL] [Abstract][Full Text] [Related]
17. Activation of HIF-1 Schoos A; Gabriel C; Knab VM; Fux DA J Pharmacol Exp Ther; 2019 Sep; 370(3):480-489. PubMed ID: 31300611 [TBL] [Abstract][Full Text] [Related]
18. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Liu D; Hou P; Liu Z; Wu G; Xing M Cancer Res; 2009 Sep; 69(18):7311-9. PubMed ID: 19706758 [TBL] [Abstract][Full Text] [Related]
19. IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation. Guo JP; Coppola D; Cheng JQ J Biol Chem; 2011 Oct; 286(43):37389-98. PubMed ID: 21908616 [TBL] [Abstract][Full Text] [Related]
20. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Chiarini F; Del Sole M; Mongiorgi S; Gaboardi GC; Cappellini A; Mantovani I; Follo MY; McCubrey JA; Martelli AM Leukemia; 2008 Jun; 22(6):1106-16. PubMed ID: 18385752 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]